1.
JACC Clin Electrophysiol
; 7(5): 682-683, 2021 05.
Article
in English
| MEDLINE | ID: covidwho-1228053
Subject(s)
Ablation Techniques/methods , COVID-19/complications , Cardiomyopathies/complications , Coronary Sinus/diagnostic imaging , Ethanol/therapeutic use , Tachycardia, Ventricular/therapy , Ventricular Septum/diagnostic imaging , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Phlebography , SARS-CoV-2 , Tachycardia, Ventricular/complications , Tachycardia, Ventricular/physiopathology
2.
Catheter Cardiovasc Interv
; 98(6): 1152-1158, 2021 11 15.
Article
in English
| MEDLINE | ID: covidwho-1201964
ABSTRACT
Refractory angina is considered a devastating condition with limited medical and therapeutic options. The Neovasc Reducer device, when implanted in the coronary sinus, is designed to alleviate anginal symptoms. However, the available clinical data are sparse. The US Food and Drug Administration (FDA) assembled the Circulatory Systems Devices Panel to discuss the Reducer's safety and effectiveness. Because of the coronavirus disease 2019 pandemic, this meeting was held virtually. In this manuscript, we detail the deliberation and discussion among the circulatory panel members, including their final vote.